Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,257 matching trials from the live ClinicalTrials.gov search.
Filters: "HNSCC" Condition: Head and Neck Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

NCT07213934
View directory record Official record
Conditions
Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Proton therapy, Pembrolizumab
Radiation · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Terminated Phase 2 Interventional

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

NCT00557206
View directory record Official record
Conditions
Neoplasms, Head and Neck Neoplasms
Interventions
Oxaliplatin and Docetaxel
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

NCT03021993
View directory record Official record
Conditions
Oral Cavity SCC
Interventions
Nivolumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 20, 2026, 1:50 PM EDT
Recruiting Phase 2 Interventional

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

NCT07392580
View directory record Official record
Conditions
Laryngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Withdrawn No phase listed Observational

Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device

NCT01133262
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 20, 2026, 1:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

NCT03085719
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of RAD001 Head and Neck Cancer

NCT01051791
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Everolimus 10mg daily
Drug
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional

PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck

NCT00011778
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
bortezomib, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 20, 2026, 1:50 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

MicroRNA Markers in Head and Neck Cancers

NCT04305366
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Tissue collection
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Terminated Phase 1 Interventional Results available

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

NCT00882583
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Dasatinib, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 20, 2026, 1:50 PM EDT
Not listed Phase 1Phase 2 Interventional

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

NCT00003251
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01836029
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
VTX-2337, Carboplatin, Cisplatin, 5-fluorouracil, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
53
States / cities
Little Rock, Arkansas • Beverly Hills, California • Escondido, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

NCT03993353
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
Interventions
Pembrolizumab, Tadalafil
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Terminated Phase 3 Interventional

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

NCT00004227
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, conventional surgery, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
3
States / cities
Lakewood, New Jersey • Long Branch, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

NCT00055770
View directory record Official record
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions
erlotinib hydrochloride, docetaxel, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

NCT00939627
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, placebo, sorafenib tosylate, laboratory biomarker analysis, quality-of-life assessment
Biological · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

NCT01612351
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00337129
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
eribulin mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
139
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 20, 2026, 1:50 PM EDT
Enrolling by invitation Phase 2 Interventional

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

NCT07062354
View directory record Official record
Conditions
Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Interventions
Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Tucson, Arizona • Irvine, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

NCT01044433
View directory record Official record
Conditions
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
lapatinib ditosylate, capecitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 20, 2026, 1:50 PM EDT
Completed Phase 1 Interventional

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

NCT01064921
View directory record Official record
Conditions
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
vorinostat, cisplatin, radiation therapy, Correlative Studies
Drug · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 20, 2026, 1:50 PM EDT